RWA Wealth Partners LLC Increases Holdings in Amgen Inc. $AMGN

RWA Wealth Partners LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 30.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,213 shares of the medical research company’s stock after buying an additional 10,588 shares during the quarter. RWA Wealth Partners LLC’s holdings in Amgen were worth $12,759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Laurel Wealth Advisors LLC boosted its stake in shares of Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares in the last quarter. Norges Bank purchased a new stake in shares of Amgen during the second quarter worth about $1,663,726,000. Vanguard Group Inc. grew its stake in shares of Amgen by 1.6% in the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after purchasing an additional 841,117 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after purchasing an additional 687,735 shares during the last quarter. Finally, Mizuho Markets Cayman LP bought a new position in Amgen during the 2nd quarter valued at approximately $135,597,000. 76.50% of the stock is currently owned by institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Market commentary highlighting recent share-strength and valuation checks has drawn fresh investor attention, supporting momentum off strong YTD and 1‑year returns. Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate
• Positive Sentiment: Multiple articles argue Amgen is a long-term value/dividend play, reinforcing buy-and-hold interest from income and value-focused investors. Why Amgen (AMGN) is a Top Value Stock for the Long-Term (Zacks)
• Positive Sentiment: Amgen scheduled a presentation at the TD Cowen Health Care Conference (March 2), giving management a platform to update on commercial outlook and the MARITIME trial timetable — a likely near‑term liquidity for investor sentiment. AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
• Neutral Sentiment: Short interest data posted shows zero shares and a short-interest ratio of 0.0 days — this appears to be a reporting anomaly and doesn’t provide a clear signal on bearish positioning.
• Neutral Sentiment: Feature pieces and retrospectives on long‑term returns (Benzinga, MSN) boost narrative momentum but are not new fundamental catalysts. If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today
• Negative Sentiment: Barclays initiated coverage with an Equal Weight rating and a $185 price target — a relatively conservative view that could cap upside and prompt some profit‑taking or more cautious positioning among institutional holders. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $382.87 on Wednesday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12. The firm’s 50-day moving average price is $345.41 and its 200-day moving average price is $317.87. The company has a market cap of $206.39 billion, a PE ratio of 26.91, a PEG ratio of 3.76 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 earnings per share. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AMGN shares. Wells Fargo & Company lifted their price objective on Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. The Goldman Sachs Group raised their price target on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Truist Financial boosted their price objective on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Finally, Leerink Partners raised their target price on shares of Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.